Learning how these processes work helps reveal why some patients experience overall health improvements and not just weight loss benefits
Researched against FDA labeling, published clinical-trial data (STEP-1 / SURMOUNT-1), and Embody's live pages, not a paid placement
Tirzepatide (Mounjaro and Zepbound) produces larger total weight loss than semaglutide on average, which means larger absolute muscle loss in numbers, even if the proportional loss is similar
These fermentable fibers serve as food for beneficial gut bacteria, which then produce short-chain fatty acids (SCFAs) such as butyrate, propionate, and acetate
Tirzepatide is a 39amino acid dual incretin receptor agonist that activates both GLP1 and GIP receptors, enhancing glucosedependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite [1] [2]
Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: a population-based cohort study